

Somnuek Sungkanuparph

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2900376/publications.pdf>

Version: 2024-02-01

114
papers

3,314
citations

201385

27
h-index

161609

54
g-index

116
all docs

116
docs citations

116
times ranked

3871
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 RT-PCR positivity of individuals subsequent to completing quarantine upon entry into a country during a transmission-free period. <i>Travel Medicine and Infectious Disease</i> , 2022, 46, 102271.	1.5	4
2	Recovery of renal function after early versus late switching of tenofovir disoproxil fumarate in people living with HIV with renal insufficiency. <i>International Journal of STD and AIDS</i> , 2022, 33, 391-396.	0.5	0
3	Spontaneous tension hemothorax in a severe COVID-19 patient receiving ECMO therapy: The other side of COVID-19-associated coagulopathy. <i>Respiratory Medicine Case Reports</i> , 2022, 37, 101663.	0.2	2
4	Metformin for Preventing Progression From Prediabetes to Diabetes Mellitus in People Living With Human Immunodeficiency Virus. <i>Cureus</i> , 2022, , .	0.2	3
5	Association between gut microbiota and prediabetes in people living with HIV. <i>Current Research in Microbial Sciences</i> , 2022, 3, 100143.	1.4	4
6	The Association of HLA-B*35 and GSTT1 Genotypes and Hepatotoxicity in Thai People Living with HIV. <i>Journal of Personalized Medicine</i> , 2022, 12, 940.	1.1	0
7	Viral Tropism in Human Immunodeficiency Virus Type 1â€“Infected Children and Adolescents in Thailand. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 1-6.	0.6	1
8	Role of clinical pharmacists in telemonitoring for patients with Coronavirus Disease 2019 (COVIDâ€“19). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 236-239.	0.7	13
9	Genomic surveillance of SARS-CoV-2 in Thailand reveals mixed imported populations, a local lineage expansion and a virus with truncated ORF7a. <i>Virus Research</i> , 2021, 292, 198233.	1.1	27
10	The association between body mass index and severity of Coronavirus Disease 2019 (COVID-19): A cohort study. <i>PLoS ONE</i> , 2021, 16, e0247023.	1.1	23
11	Assessment of atherosclerotic cardiovascular disease risks between people living with HIV receiving first-line and second-line antiretroviral therapy in a resource-limited setting. <i>International Journal of STD and AIDS</i> , 2021, 32, 421-426.	0.5	2
12	Effects of an intensive lifestyle intervention and the role of sleep in people living with HIV and prediabetes: a pilot and feasibility study. <i>BMC Research Notes</i> , 2021, 14, 145.	0.6	3
13	Mice Immunized with the Vaccine Candidate HexaPro Spike Produce Neutralizing Antibodies against SARS-CoV-2. <i>Vaccines</i> , 2021, 9, 498.	2.1	10
14	A Comparison of Bone Mineral Density and Its Predictors in HIV-Infected and HIV-Uninfected Older Men. <i>Endocrine Practice</i> , 2021, 27, 1225-1231.	1.1	0
15	Comparison between blood hemoglobin concentration determined by point-of-care device and complete blood count in adult patients with dengue. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009692.	1.3	5
16	Identifying individuals with recent COVID-19 through voice classification using deep learning. <i>Scientific Reports</i> , 2021, 11, 19149.	1.6	23
17	SARSâ€“CoVâ€“2 neutralizing antibodies decline over one year and patients with severe COVIDâ€“19 pneumonia display a unique cytokine profile. <i>International Journal of Infectious Diseases</i> , 2021, 112, 227-234.	1.5	13
18	Pulmonary function and six-minute-walk test in patients after recovery from COVID-19: A prospective cohort study. <i>PLoS ONE</i> , 2021, 16, e0257040.	1.1	37

#	ARTICLE	IF	CITATIONS
19	Anti-HIV serological test algorithms to reduce false-positive and inconclusive results for low HIV prevalence and resource-limited areas. <i>International Journal of STD and AIDS</i> , 2021, , 095646242110443.	0.5	1
20	CoronaVac induces lower neutralising activity against variants of concern than natural infection. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1352-1354.	4.6	65
21	Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people. <i>International Journal of STD and AIDS</i> , 2021, 32, 266-275.	0.5	8
22	Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes. <i>Cureus</i> , 2021, 13, e19046.	0.2	4
23	Left ventricular thrombus and pulmonary embolism: A case series of thrombosis in COVID-19 in Thai patients. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1224-1229.	1.0	7
24	<p>Clinical Characteristics of HIV-Associated Optic Neuritis</p>. <i>International Medical Case Reports Journal</i> , 2020, Volume 13, 609-616.	0.3	2
25	Correlation between plasma glucose and hemoglobin A1c in HIV-infected individuals receiving zidovudine and non-zidovudine containing antiretroviral therapy regimens. <i>HIV Research and Clinical Practice</i> , 2020, 21, 56-62.	1.1	0
26	Prediabetes among HIV-infected individuals receiving antiretroviral therapy: prevalence, diagnostic tests, and associated factors. <i>AIDS Research and Therapy</i> , 2020, 17, 25.	0.7	6
27	Switching protease inhibitors to rilpivirine in HIV-€positive individuals with complete viral suppression and without prior HIV drug resistance in a resource-€limited setting: a randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25462.	1.2	1
28	Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz297.	0.4	3
29	Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz155.	0.4	4
30	2250. Metformin for Preventing Diabetes Mellitus in HIV-Infected Patients with Prediabetes: A Randomized Controlled Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S665-S665.	0.4	1
31	External Quality Assessment Scheme for HIV-1 Drug-Resistance Genotyping in Thailand. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 1028-1035.	0.5	2
32	Prevalence of HIV infection, access to HIV care, and response to antiretroviral therapy among partners of HIV-infected individuals in Thailand. <i>PLoS ONE</i> , 2018, 13, e0198654.	1.1	3
33	Long-Term Liver Diseases after Initiation of Antiretroviral Therapy in HIV-Infected Patients with and without HBV or HCV Coinfection. <i>Journal of the International Association of Providers of AIDS Care</i> , 2017, 16, 194-200.	0.6	2
34	Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus-€Infected Patients With CD4 T-Cell Counts <100 Cells/€µL and Receiving Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2017, 64, 967-970.	2.9	10
35	Factors associated with pre-treatment HIV RNA: application for the use of abacavir and rilpivirine as the first-line regimen for HIV-infected patients in resource-limited settings. <i>AIDS Research and Therapy</i> , 2017, 14, 27.	0.7	0
36	The challenges of ending AIDS in Asia: outcomes of the Thai National AIDS Universal Coverage Programme, 2000-€2014. <i>Journal of Virus Eradication</i> , 2017, 3, 192-199.	0.3	18

#	ARTICLE	IF	CITATIONS
37	The challenges of ending AIDS in Asia: outcomes of the Thai National AIDS Universal Coverage Programme, 2000-2014. <i>Journal of Virus Eradication</i> , 2017, 3, 192-199.	0.3	12
38	Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials. <i>Infection and Chemotherapy</i> , 2016, 48, 219.	1.0	2
39	Tuberculous Panophthalmitis with Lymphadenitis and Central Nervous System Tuberculoma. <i>Case Reports in Infectious Diseases</i> , 2016, 2016, 1-7.	0.2	7
40	Primary Prophylaxis for Cryptococcosis With Fluconazole in Human Immunodeficiency Virus (HIV)-Infected Patients With CD4 Cell Counts ≤ 100 Cells/mm ³ and Receiving Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
41	Integrated therapy for HIV and cryptococcosis. <i>AIDS Research and Therapy</i> , 2016, 13, 42.	0.7	39
42	Integrated therapy for HIV and tuberculosis. <i>AIDS Research and Therapy</i> , 2016, 13, 22.	0.7	49
43	Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 818-820.	2.9	12
44	Rate of CD4 Decline and Factors Associated with Rapid CD4 Decline in Asymptomatic HIV-Infected Patients. <i>Journal of the International Association of Providers of AIDS Care</i> , 2016, 15, 3-6.	0.6	8
45	Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay. <i>PLoS ONE</i> , 2016, 11, e0147945.	1.1	9
46	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001810.	3.9	188
47	Rate of and Predicting Factors for Virologic Failure in HIV-Infected Patients with Persistent Low-Level Viremia under Antiretroviral Therapy. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015, 14, 12-16.	0.6	4
48	Risk group characteristics and viral transmission clusters in South-East Asian patients infected with human immunodeficiency virus-1 (HIV-1) circulating recombinant form (CRF) 01_AE and subtype B. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 445-453.	0.8	2
49	HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia. <i>Journal of the International AIDS Society</i> , 2014, 17, 19053.	1.2	14
50	Factors associated with suboptimal adherence to antiretroviral therapy in Asia. <i>Journal of the International AIDS Society</i> , 2014, 17, 18911.	1.2	34
51	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, e8-e16.	0.9	142
52	Coreceptor tropism determined by genotypic assay in HIV-1 circulating in Thailand, where CRF01_AE predominates. <i>HIV Medicine</i> , 2014, 15, 269-275.	1.0	13
53	Surveillance of Transmitted HIV Drug Resistance in Antiretroviral-Naive Patients Aged less than 25 Years, in Bangkok, Thailand. <i>Journal of the International Association of Providers of AIDS Care</i> , 2014, 13, 12-14.	0.6	2
54	ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2195-2201.	1.3	28

#	ARTICLE	IF	CITATIONS
55	CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 292-296.	1.1	18
56	Current status of HIV treatment in Asia and the Pacific region. <i>Sexual Health</i> , 2014, 11, 119.	0.4	9
57	Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 18804.	1.2	56
58	Transmitted Drug Resistance and Antiretroviral Treatment Outcomes in Non-Subtype B HIV-1-Infected Patients in South East Asia. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 74-79.	0.9	33
59	HIV-1 drug resistance-associated mutations among antiretroviral-naïve Thai patients with chronic HIV-1 infection. <i>Journal of Medical Virology</i> , 2013, 85, 194-199.	2.5	18
60	Transmitted HIV drug resistance in Asia. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 27-33.	1.5	20
61	Risk of cardiovascular events predicted by the Rama-EGAT score among HIV-infected patients in Thailand. <i>Southeast Asian Journal of Tropical Medicine and Public Health</i> , 2013, 44, 818-24.	1.0	2
62	Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand. <i>Journal of the International AIDS Society</i> , 2012, 15, 12-12.	1.2	28
63	Etravirine and Rilpivirine Resistance in HIV-1 Subtype Crf01_Ae-Infected Adults Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens. <i>Antiviral Therapy</i> , 2011, 16, 1113-1121.	0.6	25
64	HIV-1 Drug Resistance Mutations Among Antiretroviral-Naive HIV-1-Infected Patients in Asia: Results From the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. <i>Clinical Infectious Diseases</i> , 2011, 52, 1053-1057.	2.9	42
65	Renal impairment in HIV-1 infected patients receiving antiretroviral regimens including tenofovir in a resource-limited setting. <i>Southeast Asian Journal of Tropical Medicine and Public Health</i> , 2011, 42, 643-50.	1.0	5
66	The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. <i>Journal of Infection</i> , 2010, 60, 474-477.	1.7	90
67	Prevalence of and Risk Factors for Pre-Diabetes in HIV-1-Infected Patients in Bangkok, Thailand. <i>Journal of the International Association of Providers of AIDS Care</i> , 2010, 9, 358-361.	1.2	12
68	Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. <i>International Journal of Infectious Diseases</i> , 2010, 14, e1013-e1017.	1.5	20
69	Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 791-802.	4.6	271
70	Mortality rates in HIV-infected patients with second failure of antiretroviral therapy are still high: a lesson from NA-ACCORD. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 371-373.	2.0	0
71	Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. <i>Asian Biomedicine</i> , 2010, 4, 515-528.	0.2	74
72	The Application of Artificial Neural Networks for Phenotypic Drug Resistance Prediction: Evaluation and Comparison with Other Interpretation Systems. <i>Japanese Journal of Infectious Diseases</i> , 2010, 63, 87-94.	0.5	26

#	ARTICLE	IF	CITATIONS
73	A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2009, 48, 1775-1783.	2.9	141
74	A Randomized Trial Comparing Plasma Drug Concentrations and Efficacies between 2 Nonnucleoside Reverse Transcriptase Inhibitor-Based Regimens in HIV-Infected Patients Receiving Rifampicin: The N ₂ R Study. <i>Clinical Infectious Diseases</i> , 2009, 48, 1752-1759.	2.9	131
75	Cryptococcal Immune Reconstitution Inflammatory Syndrome after Antiretroviral Therapy in AIDS Patients with Cryptococcal Meningitis: A Prospective Multicenter Study. <i>Clinical Infectious Diseases</i> , 2009, 49, 931-934.	2.9	103
76	Reply to DiNubile. <i>Clinical Infectious Diseases</i> , 2009, 49, 811-812.	2.9	1
77	Effect of high-dose fluconazole on QT interval in patients with human immunodeficiency virus (HIV)-associated cryptococcal meningitis. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 494-496.	1.1	9
78	HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. <i>Southeast Asian Journal of Tropical Medicine and Public Health</i> , 2009, 40, 83-8.	1.0	7
79	Antiretroviral therapy in AIDS patients with CMV disease: Impact on the survival and long-term treatment outcome. <i>Journal of Infection</i> , 2008, 56, 40-43.	1.7	24
80	Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. <i>Journal of Clinical Virology</i> , 2008, 41, 310-313.	1.6	33
81	Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection. <i>Journal of Clinical Virology</i> , 2008, 43, 284-286.	1.6	4
82	Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naïve advanced HIV-infected patients in Thailand: A prospective study. <i>Current Therapeutic Research</i> , 2008, 69, 90-100.	0.5	0
83	Clinical Presentations of Newly Diagnosed HIV-Infected Patients at a University Hospital in Bangkok, Thailand. <i>Journal of the International Association of Providers of AIDS Care</i> , 2008, 7, 82-87.	1.2	14
84	Mortality Rate of Early Versus Deferred Initiation of Antiretroviral Therapy in HIV-1-Infected Patients With Cryptococcal Meningitis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 508-509.	0.9	11
85	Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis. <i>International Journal of STD and AIDS</i> , 2008, 19, 268-271.	0.5	40
86	Compliance with hepatitis B and hepatitis C virus infection screening among HIV-1 infected patients in a resource-limited setting. <i>Southeast Asian Journal of Tropical Medicine and Public Health</i> , 2008, 39, 863-6.	1.0	10
87	Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. <i>Journal of the Medical Association of Thailand = Chotmaihet Thangphaet</i> , 2008, 91, 1925-35.	0.4	15
88	Impact of Antiretroviral Therapy on the Relapse of Cryptococcosis and Survival of HIV-Infected Patients with Cryptococcal Infection. <i>Current HIV Research</i> , 2007, 5, 355-360.	0.2	41
89	Timing of Cryptococcal Immune Reconstitution Inflammatory Syndrome After Antiretroviral Therapy in Patients With AIDS and Cryptococcal Meningitis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 595-596.	0.9	44
90	HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen. <i>International Journal of STD and AIDS</i> , 2007, 18, 832-834.	0.5	4

#	ARTICLE	IF	CITATIONS
91	Options for a Second-Line Antiretroviral Regimen for HIV Type 1-Infected Patients Whose Initial Regimen of a Fixed-Dose Combination of Stavudine, Lamivudine, and Nevirapine Fails. <i>Clinical Infectious Diseases</i> , 2007, 44, 447-452.	2.9	178
92	Letter to the Editor: Tenofovir Resistance among HIV-Infected Patients Failing a Fixed-Dose Combination of Stavudine, Lamivudine, and Nevirapine in a Resource-Limited Setting. <i>AIDS Patient Care and STDs</i> , 2007, 21, 711-714.	1.1	7
93	Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. <i>BMC Infectious Diseases</i> , 2007, 7, 14.	1.3	28
94	Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting. <i>AIDS Research and Therapy</i> , 2007, 4, 26.	0.7	10
95	Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. <i>Journal of Infection</i> , 2007, 55, 464-469.	1.7	51
96	Declining prevalence of drug-resistant tuberculosis among HIV/tuberculosis co-infected patients receiving antiretroviral therapy. <i>Journal of the Medical Association of Thailand = Chotmaiht Thangphaet</i> , 2007, 90, 884-8.	0.4	4
97	Cryptococcosis in human immunodeficiency virus-negative patients. <i>International Journal of Infectious Diseases</i> , 2006, 10, 72-78.	1.5	140
98	Survival Rate and Risk Factors of Mortality Among HIV/Tuberculosis-Coinfected Patients With and Without Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 43, 42-46.	0.9	218
99	Antifungal susceptibilities of <i>Cryptococcus neoformans</i> cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis. <i>Journal of the Medical Association of Thailand = Chotmaiht Thangphaet</i> , 2006, 89, 795-802.	0.4	11
100	Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2005, 5, 67.	1.3	15
101	Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm ³ in a resource-limited setting: efficacy and tolerability. <i>International Journal of STD and AIDS</i> , 2005, 16, 243-246.	0.5	10
102	Intermittent Episodes of Detectable HIV Viremia in Patients Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based or Protease Inhibitor-Based Highly Active Antiretroviral Therapy Regimens Are Equivalent in Incidence and Prognosis. <i>Clinical Infectious Diseases</i> , 2005, 41, 1326-1332.	2.9	70
103	Cryptococcuria as a manifestation of disseminated cryptococcosis and isolated urinary tract infection. <i>Japanese Journal of Infectious Diseases</i> , 2004, 57, 203-5.	0.5	20
104	Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. <i>Journal of the Medical Association of Thailand = Chotmaiht Thangphaet</i> , 2004, 87, 1349-54.	0.4	16
105	Infections with rapidly growing mycobacteria: report of 20 cases. <i>International Journal of Infectious Diseases</i> , 2003, 7, 198-205.	1.5	63
106	Chronic Diarrhoea Caused by <i>Cryptococcus neoformans</i> in a Non-human Immunodeficiency Virus-infected Patient. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 211-212.	1.5	6
107	Discontinuation of Secondary Prophylaxis for Cryptococcal Meningitis in Human Immunodeficiency Virus-Infected Patients Treated with Highly Active Antiretroviral Therapy: A Prospective, Multicenter, Randomized Study. <i>Clinical Infectious Diseases</i> , 2003, 36, 1329-1331.	2.9	125
108	Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. <i>Aids</i> , 2003, 17, 2129-2131.	1.0	33

#	ARTICLE	IF	CITATIONS
109	Concomitant Tuberculous and Cryptococcal Thyroid Abscess in a Human Immunodeficiency Virus-infected Patient. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 68-70.	1.5	22
110	Efavirenz-Based Regimen as Treatment of Advanced AIDS With Cryptococcal Meningitis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 118-119.	0.9	11
111	Rapidly growing mycobacterial infections: spectrum of diseases, antimicrobial susceptibility, pathology and treatment outcomes. <i>Journal of the Medical Association of Thailand = Chotmai het Thangphaet</i> , 2003, 86, 772-80.	0.4	4
112	Eubacterium Bacteremia and Colon Cancer. <i>Scandinavian Journal of Infectious Diseases</i> , 2002, 34, 941-943.	1.5	6
113	Correlation between susceptibility of <i>Mycobacterium tuberculosis</i> by microtiter plate alamar blue assay and clinical outcomes. <i>Journal of the Medical Association of Thailand = Chotmai het Thangphaet</i> , 2002, 85, 820-4.	0.4	3
114	Cryptococcosis in Asia. , 0, , 287-297.		3